Impact of optimal medical therapy on the arrhytmias and heart rate variability detected with 24 hour Holter in a series of patients from a heart failure clinic;Impacto de la terapia médica en las arritmias y variabilidad de la frecuencia cardiaca detectadas por Holter de 24 horas en una serie de pacientes de una clínica de insuficiencia cardiaca

Revista de Investigacion Clinica

Volumn 56, Issue 5, 2004, Pages 609-614

  Cárdenas, Enrique ^a   Asensio Lafuente, Enrique ^a   Orea, Arturo ^a   Castillo, Lilia ^a   Narváez, René ^a   Dorantes, Joel ^a   Rebollar, Verónica ^a   Hernández, Pablo ^a   Nájera, Emma ^a   Oseguera, Jorge ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

24 Hr Holter; Heart failure; Heart rate variability; Medical treatment; Sudden death; Venticular arrhythmias

Indexed keywords

ANTIARRHYTHMIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HEALTH CARE FACILITY; HEART EJECTION FRACTION; HEART FAILURE; HEART RATE VARIABILITY; HEART VENTRICLE ARRHYTHMIA; HOLTER MONITORING; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RISK ASSESSMENT; SUDDEN DEATH; SUPRAVENTRICULAR PREMATURE BEAT; TIME; TREATMENT OUTCOME;

ARRHYTHMIA; CARDIAC CARE FACILITIES; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 19944432412     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Medscape Cardiology 2004: http://www.medscape.com/viewarticle/466090_1.
2. Orea A, Castillo L. Programa Nacional de Registro de Insuficiencia Cardiaca (PRONARICA). Boletín 1, Nov 2003.
3. De Teresa E, Alzueta J, Jiménez M. Profiling risk from arrhythmic or hemodynamic death. Am J Cardiol; 2000; 86(Suppl.): 126K-32K.
4. Ferrara R, Mastrorilli F, Pasanisi G, Censi S, D'Aiello N, Fucili A, et al. Neurohormonal modulation in chronic heart failure. Eur Heart J 2002; 4(Suppl. D): D3-D11.
5. Haq S, Choukroun G, Lim H, tymitz K, del Monte F, Gwathmey J, et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 2001; 103: 670-7.
6. Weber K. Aldosterone, in congestive heart failure. N Engl J Med 2001; 345(23): 1689-97.
7. Mann D, Spinale F. Activation of matrix metalloproteinases in the failing human heart. Breaking the tie that binds. Circulation 1998; 98: 1699-702.
8. Deedwania P. Ventricular arrhythmias and sudden death in heart failure: evaluation and management. 20th. Annual Scientific Sessions of the North American Society of Pacing and Electrophysiology, 1999: http://www.medscape.com/medscape/cno/1999/NASPE/Story.cm?story_id-585
9. Nolan J, Batin P, Andrews R, Lindsay S, Brooksby P, Mullen M et al. Prospective study of heart rate variability and mortality in chronic heart failure. Results of the United Kingdom Heart failure evaluation and assessment of risk trial (UK-Heart). Circulation 1998; 98: 1510-6.
10. Kleiger R, Stein P. Heart rate variability. In: Malik M (ed). Risk of arrhythmia and sudden death. BMJ Books; 2001, p. 221-34.
11. Packer M. Drug and dosing regimens of the 1999 heart failure consensus recommendations. Am J Cardiol 1999; 83(2A): 1A38-A.
12. Warner L. Congestive heart failure. ACC Scientific session 2000. http://www.medscape.com/medscape/cno/2000/ACC/Story.crm?story_id-1074
13. Moser M. Beta-blockers in the management of cardiovascular disease. http://medscape.com/medscape/cardiology/TreatmentUpdate/2000/tu01 /pnt-tu01.html
14. Zannad F. Evidence based drug therapy for chronic heart failure. Eur Heart J 2002; 4(Suppl.D): D66-72.
15. Gibbons R, Antman E, Alpert J, Jacobs A, Faxon D, Hiratzka H on behalf of the Task force of practice guidelines. ACC/ARA Guidelines for the evaluation and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association. http://www.americanheart.org/downloadable/heart /1013201138293HFGuidelineFinal.pdf
16. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart Rate variability. Standards of measurement physiological interpretation and clinical use. Circulation 1996; 93: 1043-65.
17. Epstein A, Bigger J, Wyse D, Romhilt D, Reynolds R, Hallstrom A. On behalf of the Cardiac Arrhythmia Suppression Trial. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-12.
18. Aliot E, de Chilou C, Sadoul N. Ventricular instability and sudden death in patients with heart failure: lessons from clinical trials. Eur Heart J 2002; 4(Suppl. D): D31-42.
19. Leclercq C, Cazeau S, Ritter P, Alonso C, Gras D, Mabo P, et al. A pilot experience with permanent biventricular pacing to treat advanced heart failure. Am Heart J 2000; 140(6): 862-70.
20. Cohen T, Klein J. Cardiac resynchronization therapy for treatment of chronic heart failure. J Invasive Cardiol 2002; 14(1 : 48-53.
21. Khaykin Y, Saad E, Wilkoff B. Pacing in heart failure: the benefit of resynchronization. Clev Clin J Med 2003; 70(10): 841-65.
22. Bristow M, Feldman A, Saxon L, for the COMPANION steering comitee and companion clinical investigators. Heart failure management using implantable devices for ventricular resynchronization: Comparison of medical therapy pacing and defibrillation in chronic heart Failure (Companion trial). J Card Fail 2000; 6: 276-85.